Register and share your invite link to earn from video plays and referrals.

Search results for 1R_Sanctuary」(
1R_Sanctuary」( community
One keyword maps to one global community path.
Create community
People
Not Found
Tweets including 1R_Sanctuary」(
🚨 BREAKING: SUPREME COURT LAUGHS VIRGINIA DEMOCRATS OUT OF THE ROOM — the 10D-1R map STAYS struck down, Dems have LOST the case LMAO! They just got pummeled by BOTH SCOTUS and the VA Supreme Court. The map will remain as-is. Hakeem Jeffries is LIVID tonight! Another win! 🔥 The DEI Attorney General Jay Jones got laughed out of court!
Show more
0
153
8.3K
1.6K
Forward to community
Had another great outing in a big win vs El Camino. 7IP 4K 0BB 5H 1R - 72 Pitches Also had a great week at the dish, 3-7 with a couple RBIs. FB, SNK, SL & a double off the wall @ Taft included below. @coachgoose_ @Dmallas1 @JoeyCohen20 @latsondheimer @Tarek_Fattal
Show more
The #Altcoin# portfolio has climbed from $75,000 to $180,000. Including trades like $GRASS that went 2x+. The daytrades that I've provided over the past two months. August: +16.1R September: +18.9R All shared for subscribers here. Join today:
Show more
🚨 IT'S OFFICIAL, WE WIN! "The US Supreme Court moments ago has ruled AGAINST Virginia Democrats when it comes to reviving their pro-Democrat redistricting map ahead of the 2026 midterms." WOULD'VE BEEN: 10D-1R MAP WILL REMAIN AS: 6D-5R Another Dem embarrassment. 🔥🔥🔥
Show more
0
136
7.9K
1.5K
Forward to community
What's next for PeptAI? - Q2 2026: First on-chain wet-lab attestation via @Molecule_sci Labs - Q3 2026: Autonomous iteration cycle proven, GLP-1R Gen 1 library, design-vs-nature bioRxiv preprint - Q4 2026: Pipeline scales beyond GPCRs - Q1 2027: Lead optimization at scale, pre-IND scoping - Q2 2027: First in vivo studies, multi-target portfolio in parallel Follow @peptai_ for live gate decisions, candidate updates, and wet-lab results.
Show more
Santi v King 4/15 game start 5IP, 69 total pitches, 5SO, 1H, 1R, 1BB FB sitting 88-90 Slider, curve & change moving tight. @SoCalBirds @RC13SPORTS @CoachCamNCSA
Kyle: 25p | 8r | 5a Cody: 24p | 7a | 2s John: 16p | 8r | 2a | 1s | 2b Kennedy: 16p | 1r | 7a | 1s Ace: 15p | 7r | 1a Brice: 13p | 4r | 6a | 2s Elijah: 11p | 4r | 2a | 2s | 2b #TakeNote# presented by @ZionsBank
Show more
Cody: 34p | 7r | 7a | 1s | 1b Brice: 22p | 3r | 1s Isaiah: 21p | 5r | 3a | 1s | 1b Elijah: 13p | 1r | 4a | 2s | 1b #TakeNote# presented by @ZionsBank
Keyonte: 30p | 4r | 2a | 1s | 5 3PM Isaiah: 18p | 5a | 3s | 1b Ace: 12p | 2r | 3a Blake: 11p | 1r #TakeNote# presented by @ZionsBank
$VRDN(Viridian Therapeutics) 5.2.1 快照:现价24.27|市值2.75B|52周区间13.18到34.29|现金及等价物212.4M|短期投资662.3M|流动性合计874.7M|季度经营现金流出105.3M|跑道8.3个季度约2.1年|年度收入70.8M|净利润-342.6M|研发338.9M|资本支出-0.5M|季度收入0.3M|季度净利润-127.1M|流动比率1264.9%|毛利率100.0%|营业利润率-512.91%|技术选股A组分数78、硬条件命中、获利盘95.52%、套牢盘4.48%、90%集中度20.16(来源Nasdaq财报接口与技术选股 10/29/2026) 5.2.2 主营业务与产品技术亮点:专注甲状腺眼病等自身免疫罕见病抗体药物开发,属生物医药创新大类创新药基因子行业;核心管线为长效IGF-1R抗体,走皮下注射路线以替代静脉给药;管线形态为单一适应症深耕加多适应症拓展;客户与产业链位置为自研自产、面向专科内分泌与眼科渠道(业务描述,无数字) 5.2.3 事件促发点:FDA批准Lumvoa后估值重估讨论,已发生2026-10-28,量级中等,利多(来源Google News Simply Wall St 10/28/2026);财报日未在数据块未来5日日历中列出,暂无已公开促发点 5.2.4 大行研报与消息汇总:Nasdaq分析师库买入12家持有0家卖出0家,目标价均值34.11、区间22.0到41.0,距现价约40.5%(来源Nasdaq分析师库 10/29/2026);消息面Simply Wall St称FDA批准Lumvoa后估值仍偏低(来源Google News 10/28/2026);头部机构专项目标价本次未采集 5.2.5 关键价位、触发与失效:日线支撑筹码峰22.0距现价10.32%|日线压力20日高24.42距现价0.62%|周线支撑周线MA10 21.46距现价11.58%|周线压力52周高34.29距现价41.29%(来源个股筹码四元组 10/29/2026);触发为放量站稳24.42;失效为跌破22.0;资金共振同向2项 5.2.6 情景:牛档34.29(周线压力52周高,从现价空间41.29%);基准档24.42(日线压力20日高);熊档21.46(周线支撑周线MA10) 5.2.7 结论:可买,1到2周期望先看24.42再看34.29,赔率约1比2以上,建议半仓,最大风险为临床与商业化节奏不及预期。
Show more